Lactate Signals in Diabetic Kidney Disease

This single-study briefing examines whether serum lactate tracks renal dysfunction in diabetic kidney disease (DKD) and what protein-centered mechanisms may contextualize that association. The investigators combined a DKD-like rat experiment, analysis of an ICU-based clinical cohort, external cohort validation, and network-based bioinformatics; the work was framed as exploratory. (pmid:42743268)

Evidence

The animal model combined right nephrectomy with streptozotocin-induced diabetes to generate a DKD-like renal-injury phenotype. Investigators assessed serum lactate and kidney-function markers with biochemical measurements and used histopathological staining to characterize renal injury. In partial Spearman analysis controlling for experimental group, lactate and cystatin C were positively associated (ρ = 0.748, P = 0.0081). The reported clinical and pathological observations in model rats included elevated lactate and evidence of kidney injury. (pmid:42743268)

The clinical analysis retained 593 patients with confirmed DKD from MIMIC-IV. DKD classification used ICD coding during the first hospitalization, and the data were queried with SQL using PostgreSQL 16.6 and Navicat Premium 17. Clinical associations were examined with correlation and multivariable regression. In the reported adjusted clinical analysis, elevated lactate was independently associated with higher serum creatinine (β = 0.13, 95% CI: 0.004–0.256, P = 0.044). (pmid:42743268)

The authors tested the clinical association in an independent eICU Collaborative Research Database cohort, applying the same exposure variable, renal outcome, and hierarchical regression framework. The exposure was the earliest lactate measured within the first 24 hours after ICU admission, and the renal outcome was the first serum creatinine measured after admission. The abstract reports that the positive association was supported in this external cohort, without presenting an additional effect estimate in the available evidence. (pmid:42743268)

For molecular context, the study used target prediction, protein-protein interaction analysis, enrichment analysis, and molecular docking. The network analysis nominated hub proteins including PTGS2, EGFR, TP53, ESR1, MAPK3, and MMP9, with pathway enrichment centered on inflammation, fibrosis, and metabolism-related processes. These results identify candidate pathways linked to the lactate–DKD association; they do not establish that any nominated protein mediates the clinical association. (pmid:42743268)

Analysis — Interpretation of the protein signal

The study’s central signal is an association, observed across its experimental and ICU-based clinical components, between higher lactate and less favorable renal-function measures in DKD. The rat result connects lactate with cystatin C, whereas the clinical regression connects elevated lactate with serum creatinine. Because these are different settings, models, and renal measures, the findings are best read as convergent exploratory evidence rather than as one interchangeable estimate of disease severity. The external eICU analysis adds a replication-oriented element because it used the same exposure, outcome, and hierarchical regression approach, although the evidence available here does not provide its separate numerical result. (pmid:42743268)

The protein and pathway work extends interpretation from an observed metabolite–renal-function relationship to plausible biological contexts. Inflammation, fibrosis, and metabolism-related pathways fit the study’s stated aim of exploring molecular links, and the named hub proteins are useful candidates for experimental prioritization. However, network overlap and docking address computational connectivity and structural plausibility, not protein abundance in patient samples, causal action, therapeutic responsiveness, or clinical utility. The authors consequently interpret lactate as potentially reflecting concurrent metabolic and hemodynamic stress related to renal dysfunction rather than as a DKD-specific biomarker or causal mediator. Statistical association, including the reported regression P value, should not be treated as evidence of clinical significance by itself. (pmid:42743268)

Limitations

The animal system was a composite unilateral-nephrectomy plus streptozotocin model selected to produce a DKD-like phenotype within the experimental timeframe. It was not designed to separate the independent contributions of nephrectomy and hyperglycemia. The partial Spearman result also warrants caution because the authors note a small sample size and potential between-group separation. (pmid:42743268)

In the MIMIC-IV analysis, ICD-based identification of DKD permits possible misclassification, and uniform confirmation with albuminuria or longitudinal eGFR data was not feasible for all admissions. The eICU sample size is not located in the available evidence, and rat sample size is likewise not located. The computational analyses are hypothesis-generating and require further experimental validation; docking scores were not interpreted as binding affinities, biological activity, or in vivo effect sizes. (pmid:42743268)